Last week, an FDA advisory panel voted 19 to 5 that the Ortho Evra birth control patch should remain on the market, finding that its benefits outweigh its potential risk for blood clots. While the panel’s final vote ultimately backed the continued use of the patch, it also recommended that information regarding the increased risk [...]
